S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities

Vaccine Stocks List

Compare vaccine stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$81.39
-3.1%
$85.87
$57.17
$89.74
$102.08B0.396.53 million shs10.76 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$176.35
+1.2%
$186.42
$115.03
$217.25
$67.75B1.653.89 million shs4.03 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$12.01
+6.9%
$12.68
$8.75
$101.39
$942.79M1.737.39 million shs9.55 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$165.54
+0.4%
$174.84
$155.72
$186.69
$432.80B0.548.20 million shs10.06 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$44.34
+0.8%
$49.16
$41.44
$56.32
$248.89B0.6326.47 million shs35.16 million shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-3.11%-2.67%-4.68%+1.31%+23.66%
Moderna, Inc. stock logo
MRNA
Moderna
+1.18%-8.74%-1.47%+11.33%+3.97%
Novavax, Inc. stock logo
NVAX
Novavax
+6.95%+9.38%+22.68%-38.09%-86.57%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.38%-1.98%-7.10%-3.46%-4.18%
Pfizer Inc. stock logo
PFE
Pfizer
+0.84%+0.20%-13.50%-6.10%-17.68%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.954 of 5 stars
2.25.02.54.13.72.52.5
Moderna, Inc. stock logo
MRNA
Moderna
2.1963 of 5 stars
2.33.00.04.61.83.31.3
Novavax, Inc. stock logo
NVAX
Novavax
1.9005 of 5 stars
3.11.00.04.71.80.80.6
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
3.252 of 5 stars
3.25.04.23.93.52.51.9
Pfizer Inc. stock logo
PFE
Pfizer
3.4681 of 5 stars
3.25.05.04.52.81.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.47
Hold$87.407.38% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.45
Hold$192.008.87% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.29
Hold$92.50670.19% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$185.2311.89% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.33
Hold$52.1317.58% Upside

Current Analyst Ratings

Latest Vaccine Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/1/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$215.00
2/1/2023
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$45.00
2/1/2023
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight$53.00 ➝ $45.00
2/1/2023
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$75.00
2/1/2023
Pfizer Inc. stock logo
PFE
Pfizer
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform$49.00 ➝ $48.00
2/1/2023
Pfizer Inc. stock logo
PFE
Pfizer
Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral$50.00 ➝ $46.00
2/1/2023
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform$55.00 ➝ $53.00
2/1/2023
Pfizer Inc. stock logo
PFE
Pfizer
Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform$54.00 ➝ $50.00
2/1/2023
Pfizer Inc. stock logo
PFE
Pfizer
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight$49.00 ➝ $44.00
1/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
1/26/2023
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$55.00 ➝ $47.00
(Data available from 2/2/2020 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.31B3.74$8.69 per share9.37$16.79 per share4.85
Moderna, Inc. stock logo
MRNA
Moderna
$18.47B3.67$30.83 per share5.72$34.89 per share5.05
Novavax, Inc. stock logo
NVAX
Novavax
$1.15B0.82N/AN/A($4.65) per share-2.58
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.94B4.56$12.92 per share12.81$28.12 per share5.89
Pfizer Inc. stock logo
PFE
Pfizer
$100.33B2.48$7.39 per share6.00$13.80 per share3.21

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$6.23B$2.6530.7112.020.8112.29%38.51%12.35%2/2/2023 (Confirmed)
Moderna, Inc. stock logo
MRNA
Moderna
$12.20B$27.646.38150.73N/A55.00%70.03%45.09%2/23/2023 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$1.74B-$17.30N/AN/AN/A-71.59%N/A-51.33%2/27/2023 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$17.94B$6.7424.5615.172.8118.90%35.94%15.27%4/18/2023 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$21.98B$5.488.0910.381.4631.27%43.02%19.70%5/2/2023 (Estimated)

Latest Vaccine Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/2/2023N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.49$1.67+$0.18N/A$6.63 billion$7.39 billion  
1/31/2023Q4 2022
Pfizer Inc. stock logo
PFE
Pfizer
$1.03$1.14+$0.11$1.41$24.40 billion$24.30 billion    
1/24/2023Q4 22
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.22$2.35+$0.13$3.37$23.90 billion$23.71 billion    
11/8/2022Q3 2022
Novavax, Inc. stock logo
NVAX
Novavax
$2.21-$2.15-$4.36-$2.15$555.50 million$734.58 million      
11/3/2022Q3 2022
Moderna, Inc. stock logo
MRNA
Moderna
$3.04$2.53-$0.51$2.53$3.33 billion$3.36 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.923.59%+5.03%110.19%7 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.522.73%+5.87%67.06%61 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.643.70%+3.31%29.93%12 Years

Latest Vaccine Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/3/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Quarterly$1.132.54%2/17/20232/21/20233/7/2023
12/9/2022
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.413.16%1/26/20231/27/20233/3/2023
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.14
1.30
1.16
Moderna, Inc. stock logo
MRNA
Moderna
0.05
2.10
1.80
Novavax, Inc. stock logo
NVAX
Novavax
N/A
1.06
1.01
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.37
1.43
1.18
Pfizer Inc. stock logo
PFE
Pfizer
0.35
1.59
1.37

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
78.72%
Moderna, Inc. stock logo
MRNA
Moderna
63.11%
Novavax, Inc. stock logo
NVAX
Novavax
45.7%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
67.94%
Pfizer Inc. stock logo
PFE
Pfizer
67.62%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
17.3%
Novavax, Inc. stock logo
NVAX
Novavax
2.1%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.35%
Pfizer Inc. stock logo
PFE
Pfizer
0.05%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
14,4001.25 billion1.25 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
2,700384.18 million317.72 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,54178.50 million76.86 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
141,7002.61 billion2.61 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
79,0005.61 billion5.61 billionOptionable

Vaccine Stocks Headlines

SourceHeadline
Pfizer Inc. (NYSE:PFE) Given Average Rating of "Hold" by BrokeragesPfizer Inc. (NYSE:PFE) Given Average Rating of "Hold" by Brokerages
marketbeat.com - February 3 at 1:26 AM
Pfizer (PFE) Q4 earnings 2022 - CNBCPfizer (PFE) Q4 earnings 2022 - CNBC
news.google.com - February 2 at 6:47 PM
Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact SalesBristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales
finance.yahoo.com - February 2 at 6:47 PM
COVID is pretty much out of the models for pharma companies: Wells Fargo analystCOVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst
finance.yahoo.com - February 2 at 6:47 PM
Cathie Woods Ark Innovation ETF Set To Rebound in 2023? (PFE)Cathie Woods' Ark Innovation ETF Set To Rebound in 2023? (PFE)
marketbeat.com - February 2 at 1:50 PM
Pfizers former CFO says you should ask yourself these questions if you want to become a finance chiefPfizer's former CFO says you should ask yourself these questions if you want to become a finance chief
fortune.com - February 2 at 9:18 AM
Pfizer (NYSE:PFE) Sees Strong Trading Volume After Strong EarningsPfizer (NYSE:PFE) Sees Strong Trading Volume After Strong Earnings
americanbankingnews.com - February 2 at 9:02 AM
Pfizer (PFE) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo FinancePfizer (PFE) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
news.google.com - February 2 at 8:46 AM
Pfizer Inc. (NYSE:PFE) Q4 2022 Earnings Call Transcript - Yahoo FinancePfizer Inc. (NYSE:PFE) Q4 2022 Earnings Call Transcript - Yahoo Finance
news.google.com - February 2 at 8:46 AM
The Covid pandemic drives Pfizers 2022 revenue to a record $100 billion - CNBCThe Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion - CNBC
news.google.com - February 2 at 8:46 AM
Pfizer (NYSE:PFE) Price Target Cut to $48.00 by Analysts at SVB LeerinkPfizer (NYSE:PFE) Price Target Cut to $48.00 by Analysts at SVB Leerink
americanbankingnews.com - February 2 at 7:51 AM
Pfizer (NYSE:PFE) Price Target Cut to $50.00 by Analysts at Credit Suisse GroupPfizer (NYSE:PFE) Price Target Cut to $50.00 by Analysts at Credit Suisse Group
americanbankingnews.com - February 2 at 7:51 AM
Pfizer (NYSE:PFE) Earns "Overweight" Rating from Cantor FitzgeraldPfizer (NYSE:PFE) Earns "Overweight" Rating from Cantor Fitzgerald
americanbankingnews.com - February 2 at 7:10 AM
Pfizer (NYSE:PFE) Given New $44.00 Price Target at BarclaysPfizer (NYSE:PFE) Given New $44.00 Price Target at Barclays
americanbankingnews.com - February 2 at 5:56 AM
Pfizer (NYSE:PFE) PT Lowered to $45.00 at Morgan StanleyPfizer (NYSE:PFE) PT Lowered to $45.00 at Morgan Stanley
americanbankingnews.com - February 2 at 5:22 AM
How much will Pfizer make from covid products in 2023 - QuartzHow much will Pfizer make from covid products in 2023 - Quartz
news.google.com - February 2 at 1:11 AM
Pfizer is expecting its covid windfall to end in 2023Pfizer is expecting its covid windfall to end in 2023
finance.yahoo.com - February 1 at 8:10 PM
Novavax Shares Jumped in January While Others Slipped (PFE)Novavax Shares Jumped in January While Others Slipped (PFE)
marketbeat.com - February 1 at 7:01 PM
Pfizer Loses $43 Billion of Value in Worst Month Since 2009 - BloombergPfizer Loses $43 Billion of Value in Worst Month Since 2009 - Bloomberg
news.google.com - February 1 at 3:09 PM
U.S. FDA removes COVID test requirements for Pfizer, Merck pills - ReutersU.S. FDA removes COVID test requirements for Pfizer, Merck pills - Reuters
news.google.com - February 1 at 3:09 PM
What James Gunn had to say about Zachary Levis Pfizer tweet - Los Angeles TimesWhat James Gunn had to say about Zachary Levi's Pfizer tweet - Los Angeles Times
news.google.com - February 1 at 3:09 PM
Company News for Feb 1, 2023Company News for Feb 1, 2023
finance.yahoo.com - February 1 at 3:09 PM
Video of Pfizer Employee Explaining COVID Vaccine Research ... - Medpage TodayVideo of Pfizer Employee Explaining COVID Vaccine Research ... - Medpage Today
news.google.com - February 1 at 10:09 AM
Pfizer sees COVID-19 product sales plummeting in 2023 - FiercePharmaPfizer sees COVID-19 product sales plummeting in 2023 - FiercePharma
news.google.com - February 1 at 10:09 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Novavax logo

Novavax

NASDAQ:NVAX
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.